Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hills, Robert"" wg kryterium: Autor


Tytuł :
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Autorzy :
Zabkiewicz J; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Lazenby M; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Edwards G; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Bygrave CA; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Omidvar N; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Zhuang L; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Knapper S; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Guy C; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Hills RK; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Burnett AK; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Alvares CL; Academic Department of Haematology, University of Cardiff, H, eath Park, Cardiff, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Oct; Vol. 191 (2), pp. 231-242. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/enzymology
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/pathology
Models, Biological*
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
fms-Like Tyrosine Kinase 3*/genetics
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Adolescent ; Adult ; Aged ; Bridged-Ring Compounds/pharmacology ; Cell Adhesion/drug effects ; Child ; Child, Preschool ; Extracellular Signal-Regulated MAP Kinases ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Neoplasm, Residual ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology
Czasopismo naukowe
Tytuł :
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
Autorzy :
Linch DC; Department of Haematology, UCL Cancer Institute, London, UK.
Hills RK; Nuffield Department of Population Health, Oxford University, Oxford, UK.
Burnett AK; Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
Gale RE; Department of Haematology, UCL Cancer Institute, London, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (3), pp. e81-e86. Date of Electronic Publication: 2020 Jan 31.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA (Cytosine-5-)-Methyltransferases/*metabolism
Leukemia, Myeloid, Acute/*genetics
Adolescent ; Adult ; Aged ; Alleles ; Female ; Gene Frequency ; Humans ; Leukemia, Myeloid, Acute/enzymology ; Male ; Middle Aged ; Mutation ; Young Adult
Raport
Tytuł :
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
Autorzy :
Linch DC; Department of Haematology, UCL Cancer Institute, London, UK.
Hills RK; Nuffield Department of Population Health, Oxford, UK.
Burnett AK; Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
Russell N; Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, UK.
Gale RE; Department of Haematology, UCL Cancer Institute, London, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Mar; Vol. 188 (6), pp. 852-859. Date of Electronic Publication: 2019 Oct 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute/*genetics
Nuclear Proteins/*metabolism
Adolescent ; Adult ; Alleles ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Prognosis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Autorzy :
Dillon R; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.; Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom.; Department of Haematology, Guy's Hospital, London, United Kingdom.
Hills R; Nuffield Department of Population Health, University of Oxford, United Kingdom.
Freeman S; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Potter N; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.; Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom.
Jovanovic J; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
Ivey A; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
Kanda AS; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
Runglall M; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
Foot N; Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom.
Valganon M; Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom.
Khwaja A; Department of Haematology, University College, London, United Kingdom.
Cavenagh J; Bart's Hospital, London, United Kingdom.
Smith M; Bart's Hospital, London, United Kingdom.
Ommen HB; University Hospital, Aarhus, Denmark.
Overgaard UM; Rigshospitalet, Copenhagen, Denmark.
Dennis M; Christie Hospital, Manchester, United Kingdom.
Knapper S; Department of Haematology, Cardiff University, Cardiff, United Kingdom.
Kaur H; Royal Hallamshire Hospital, Sheffield, United Kingdom.
Taussig D; Royal Marsden Hospital, Sutton, United Kingdom.
Mehta P; Bristol Haematology and Oncology Centre, Bristol, United Kingdom.
Raj K; Department of Haematology, Guy's Hospital, London, United Kingdom.
Novitzky-Basso I; Beatson Cancer Centre, Glasgow, United Kingdom.
Nikolousis E; Heartlands Hospital, Birmingham, United Kingdom.
Danby R; Churchill Hospital, Oxford, United Kingdom.
Krishnamurthy P; Addenbrooke's Hospital, Cambridge, United Kingdom.
Hill K; University Hospital, Southampton, United Kingdom.
Finnegan D; Belfast City Hospital, Belfast, United Kingdom.
Alimam S; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.; Department of Haematology, Guy's Hospital, London, United Kingdom.
Hurst E; Royal Victoria Infirmary, Newcastle, United Kingdom.
Johnson P; Western General Hospital, Edinburgh, United Kingdom.
Khan A; St James' Hospital, Leeds, United Kingdom.
Salim R; Clatterbridge Cancer Centre, Liverpool, United Kingdom.
Craddock C; Queen Elizabeth Hospital, Birmingham, United Kingdom.
Spearing R; Christchurch Hospital, Christchurch, New Zealand.
Gilkes A; Department of Haematology, Cardiff University, Cardiff, United Kingdom.
Gale R; Department of Haematology, University College, London, United Kingdom.
Burnett A; Blackwaterfoot, Isle of Arran, United Kingdom; and.
Russell NH; Department of Haematology, Guy's Hospital, London, United Kingdom.; Nottingham University Hospital, Nottingham, United Kingdom.
Grimwade D; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.; Department of Haematology, Guy's Hospital, London, United Kingdom.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Feb 27; Vol. 135 (9), pp. 680-688.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Neoplasm, Residual*/diagnosis
Neoplasm, Residual*/genetics
Leukemia, Myeloid, Acute/*genetics
Leukemia, Myeloid, Acute/*therapy
Nuclear Proteins/*genetics
Adolescent ; Adult ; Aged ; Female ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/mortality ; Recurrence ; Young Adult
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.
Autorzy :
Kayser S; Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany .; German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Hills RK; Cardiff University School of Medicine, Cardiff, UK.
Luskin MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brunner AM; Massachusetts General Hospital, Boston, MA, USA.
Terré C; Laboratory of Hematology, André Mignot Hospital, Le Chesnay, France.
Westermann J; Department of Hematology, Oncology and Tumor Immunology, Charité-University Medical Center, Campus Virchow Clinic, Berlin, Germany.
Menghrajani K; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Shaw C; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA.
Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Elliott MA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Perl AE; Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Ráčil Z; Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Mayer J; Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Zak P; 4 Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic.
Szotkowski T; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
de Botton S; Université Paris-Saclay, Gustave Roussy Villejuif, France.
Grimwade D; Department of Medical & Molecular Genetics, King's College London, Faculty of Life Sciences and Medicine, London, UK.
Mayer K; Medical Clinic III for Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Krämer A; Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.; German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Burnett AK; Cardiff University School of Medicine, Cardiff, UK.
Ho AD; Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
Platzbecker U; Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
Thiede C; Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Ehninger G; Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Röllig C; Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA.
Müller-Tidow C; Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
Russell NH; Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Schlenk RF; NCT Trial Center, National Center for Tumor Diseases, Heidelberg, Germany.
Levis MJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2020 Jan; Vol. 105 (1), pp. 161-169. Date of Electronic Publication: 2019 Apr 19.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/therapy
Adult ; Cytarabine ; Disease-Free Survival ; Humans ; Middle Aged ; Remission Induction ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
Autorzy :
Hills RK; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Jan; Vol. 188 (1), pp. 29-35. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji :
Historical Article; Journal Article; Review
MeSH Terms :
Leukemia, Myeloid, Acute/*history
Leukemia, Myeloid, Acute/*therapy
Female ; History, 20th Century ; History, 21st Century ; Humans ; Male ; Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; United Kingdom
Czasopismo naukowe
Tytuł :
Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
Autorzy :
Burnett AK; Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK.
Hills RK; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Russell N; Department of Haematology, Centre for Clinical Haematology, Nottingham University Hospital (City Campus), Nottingham, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Jan; Vol. 188 (1), pp. 86-100. Date of Electronic Publication: 2019 Dec 11.
Typ publikacji :
Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/history
Aged ; Clinical Trials as Topic/history ; Female ; History, 20th Century ; History, 21st Century ; Humans ; Male ; United Kingdom
Czasopismo naukowe
Tytuł :
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.
Autorzy :
Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Hills RK; Centre for Trials Research Cardiff University, Cardiff, UK.
Russell NH; Nottingham University Hospital, Nottingham, UK.
Cloos J; Amsterdam UMC, Location VUMC, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Kelder A; Amsterdam UMC, Location VUMC, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Ossenkoppele GJ; Amsterdam UMC, Location VUMC, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Schuurhuis GJ; Amsterdam UMC, Location VUMC, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors :
UK NCRI AML Trial Group
HOVON AML Trial Group
Źródło :
British journal of haematology [Br J Haematol] 2019 Jul; Vol. 186 (1), pp. 130-133. Date of Electronic Publication: 2018 Dec 05.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Flow Cytometry/*methods
Leukemia, Myeloid, Acute/*drug therapy
Neoplasm, Residual/*diagnosis
Adult ; Female ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Male
Raport
Tytuł :
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Autorzy :
Basheer F; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Giotopoulos G; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Meduri E; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Yun H; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Mazan M; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Wellcome Trust Sanger Institute, Hinxton, UK.
Sasca D; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Gallipoli P; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Marando L; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Gozdecka M; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Wellcome Trust Sanger Institute, Hinxton, UK.
Asby R; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Sheppard O; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Dudek M; Wellcome Trust Sanger Institute, Hinxton, UK.
Bullinger L; Charité University Hospital, Berlin, Germany.
Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Dillon R; Department of Medical and Molecular Genetics, Kings College School of Medicine, UK.
Freeman S; Department of Clinical Immunology, University of Birmingham Medical School, Edgbaston, Birmingham, UK.
Ottmann O; Department of Haematology, University of Cardiff, Cardiff, UK.
Burnett A; Isle of Arran, UK.
Russell N; Department of Haematology, University of Nottingham, Nottingham, UK.
Papaemmanuil E; Departments of Epidemiology and Biostatistics and Cancer Biology, the Center for Molecular Oncology and the Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.
Hills R; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Campbell P; Wellcome Trust Sanger Institute, Hinxton, UK.
Vassiliou GS; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Wellcome Trust Sanger Institute, Hinxton, UK.
Huntly BJP; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK .; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK.
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2019 Apr 01; Vol. 216 (4), pp. 966-981. Date of Electronic Publication: 2019 Mar 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Disease Progression*
Loss of Function Mutation*
Enhancer of Zeste Homolog 2 Protein/*genetics
Leukemia, Myeloid, Acute/*genetics
Leukemia, Myeloid, Acute/*mortality
Animals ; Bone Marrow Cells/metabolism ; Bone Marrow Transplantation ; Cell Line, Tumor ; Cohort Studies ; Disease Models, Animal ; Gene Frequency ; Histones/metabolism ; Humans ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/pathology ; Mice ; Mice, Inbred C57BL ; Prognosis ; Survival Rate ; Transduction, Genetic ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Autorzy :
Christen F; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Hoyer K; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Yoshida K; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hou HA; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Waldhueter N; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Hills RK; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
Chan W; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Hablesreiter R; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Blau O; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Ochi Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Klement P; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Chou WC; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Blau IW; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.
Tang JL; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Zemojtel T; Berlin Institute of Health Core Genomics Facility, Charité, University Medical Center, Berlin, Germany.
Shiraishi Y; Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shiozawa Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Löwenberg B; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Linch DC; Department of Haematology, University College London Cancer Institute, London, United Kingdom; and.
Bullinger L; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.
Valk PJM; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Tien HF; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Gale RE; Department of Haematology, University College London Cancer Institute, London, United Kingdom; and.
Ogawa S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Damm F; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Department of Hematology, Oncology, and Tumor Immunology, Berlin Institute of Health, Berlin, Germany.; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.
Pokaż więcej
Źródło :
Blood [Blood] 2019 Mar 07; Vol. 133 (10), pp. 1140-1151. Date of Electronic Publication: 2019 Jan 04.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Clonal Evolution*
Mutation*
Translocation, Genetic*
Leukemia, Myeloid, Acute/*genetics
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Alleles ; Chromosomes, Human, Pair 21 ; Chromosomes, Human, Pair 8 ; DNA Mutational Analysis ; Female ; GTP Phosphohydrolases/genetics ; Genomics ; Humans ; Male ; Membrane Proteins/genetics ; Middle Aged ; Neoplasm Recurrence, Local ; Prognosis ; Proto-Oncogene Proteins p21(ras)/genetics ; Remission Induction ; Signal Transduction ; Young Adult
Czasopismo naukowe
Tytuł :
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Autorzy :
Burnett AK; Formerly Department of Haematology, Cardiff University School of Medicine, UK .
Das Gupta E; Department of Haematology, Nottingham University Hospital NHS Trust, UK.
Knapper S; Department of Haematology, University Hospital of Wales, Cardiff, UK.
Khwaja A; University College, London Cancer Institute, UK.
Sweeney M; Department of Haematology, University Hospital of Wales, Cardiff, UK.
Kjeldsen L; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
Hawkins T; Department of Haematology, Auckland City Hospital, New Zealand.
Betteridge SE; Centre for Trials Research, Cardiff University School of Medicine, UK.
Cahalin P; Department of Haematology, Blackpool Victoria Hospital, UK.
Clark RE; Department of Haematology, Royal Liverpool University Hospital, UK.
Hills RK; Department of Haematology, Royal Liverpool University Hospital, UK.
Russell NH; Department of Haematology, Nottingham University Hospital NHS Trust, UK.
Pokaż więcej
Corporate Authors :
UK NCRI AML Study Group
Źródło :
Haematologica [Haematologica] 2018 Oct; Vol. 103 (10), pp. 1654-1661. Date of Electronic Publication: 2018 Jul 05.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Consolidation Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/mortality
Everolimus/*administration & dosage
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Adolescent ; Adult ; Aged ; Disease-Free Survival ; Everolimus/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Autorzy :
Freeman SD; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Hills RK; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Virgo P; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Khan N; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Couzens S; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Dillon R; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Gilkes A; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Upton L; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Nielsen OJ; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Cavenagh JD; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Jones G; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Khwaja A; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Cahalin P; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Thomas I; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Grimwade D; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Burnett AK; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Russell NH; Sylvie D. Freeman and Naeem Khan, University of Birmingham, Birmingham; Robert K. Hills, Amanda Gilkes, Laura Upton, Ian Thomas, and Alan K. Burnett, Cardiff University; Steve Couzens University Hospital of Wales, Cardiff; Paul Virgo, North Bristol NHS Trust, Bristol; Richard Dillon and David Grimwade, King's College London School of Medicine; James D. Cavenagh, Queen Mary University of London; Asim Khwaja, University College London, London; Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle; Paul Cahalin, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool; Nigel H. Russell, Nottingham University Hospital, Nottingham, United Kingdom; Ove Juul Nielsen, Rigshospitalet, Copenhagen, Denmark.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 May 20; Vol. 36 (15), pp. 1486-1497. Date of Electronic Publication: 2018 Mar 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Induction Chemotherapy/*methods
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Neoplasm, Residual/*drug therapy
Neoplasm, Residual/*genetics
Adolescent ; Adult ; Aged ; Cytarabine/administration & dosage ; Daunorubicin/administration & dosage ; Female ; Flow Cytometry ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Nuclear Proteins/genetics ; Prospective Studies ; Risk Factors ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.
Autorzy :
Lucas CM; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.; Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; and.
Scott LJ; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Carmell N; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Holcroft AK; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Hills RK; Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Burnett AK; Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Clark RE; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.; Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; and.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2018 May 08; Vol. 2 (9), pp. 964-968.
Typ publikacji :
Journal Article
MeSH Terms :
Autoantigens/*metabolism
Biomarkers, Tumor/*metabolism
Carrier Proteins/*metabolism
Leukemia, Myeloid, Acute/*metabolism
Membrane Proteins/*metabolism
Nuclear Proteins/*metabolism
Protein Phosphatase 2/*metabolism
Proto-Oncogene Proteins c-akt/*metabolism
Adult ; Female ; Humans ; Intracellular Signaling Peptides and Proteins ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Phosphorylation
Czasopismo naukowe
Tytuł :
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Autorzy :
Schuurhuis GJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Freeman S; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Béné MC; Hematology Biology, University Hospital Nantes, Nantes, France.
Buccisano F; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Cloos J; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Grimwade D; Division of Genetics & Molecular Medicine, King's College, London, United Kingdom.
Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany.
Hills RK; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
Hourigan CS; Myeloid Malignancies Section, National Institutes of Health, Bethesda, MD.
Jorgensen JL; Division of Pathology/Laboratory Medicine, Department of Hematopathology, MD Anderson Cancer Center, Houston, TX.
Kern W; MLL Munich Leukemia Laboratory, Munich, Germany.
Lacombe F; Flow Cytometry Platform, University Hospital, Bordeaux, France.
Maurillo L; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Preudhomme C; Center of Pathology, Laboratory of Hematology, University Hospital of Lille, Lille, France.
van der Reijden BA; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Thiede C; Universitätsklinikum Carl Gustav Garus an der Technischen Universität Dresden, Dresden, Germany.
Venditti A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Vyas P; Medical Research Council Molecular Haematology Unit, Oxford Centre for Haematology, University of Oxford and Oxford University Hospitals National Health Service Trust, Oxford, United Kingdom.
Wood BL; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Laboratory Medicine and.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.
Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; and.
Roboz GJ; Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
Ossenkoppele GJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Blood [Blood] 2018 Mar 22; Vol. 131 (12), pp. 1275-1291. Date of Electronic Publication: 2018 Jan 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Clinical Trials as Topic ; Consensus Development Conferences as Topic ; Europe ; Guidelines as Topic ; Humans ; Leukemia, Myeloid, Acute/pathology ; Neoplasm, Residual ; Prognosis ; United States
Czasopismo naukowe
Tytuł :
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
Autorzy :
Tiong IS; a Department of Clinical Haematology , Alfred Hospital , Melbourne , Australia.; b Australian Centre for Blood Diseases, Monash University , Melbourne , Australia.
Tan P; a Department of Clinical Haematology , Alfred Hospital , Melbourne , Australia.
McManus J; c Department of Pathology , Alfred Hospital , Melbourne , Australia.
Cummings N; c Department of Pathology , Alfred Hospital , Melbourne , Australia.
Sadawarte S; a Department of Clinical Haematology , Alfred Hospital , Melbourne , Australia.
Catalano J; d Department of Haematology , Frankston Hospital , Frankston , Australia.
Hills R; e Department of Haematology , Cardiff University School of Medicine , Cardiff , UK.
Wei A; a Department of Clinical Haematology , Alfred Hospital , Melbourne , Australia.; b Australian Centre for Blood Diseases, Monash University , Melbourne , Australia.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2018 Feb; Vol. 59 (2), pp. 493-496. Date of Electronic Publication: 2017 Jun 08.
Typ publikacji :
Clinical Trial, Phase I; Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/administration & dosage ; Everolimus/administration & dosage ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Survival Analysis ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Treatment Outcome
Raport
Tytuł :
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
Autorzy :
Gale RE; Department of Haematology, University College London Cancer Institute, London, United Kingdom.
Popa T; Department of Haematology, University College London Cancer Institute, London, United Kingdom.
Wright M; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
Khan N; Institute of Immunology and Immunotherapy, Department of Clinical Immunology, University of Birmingham, Birmingham, United Kingdom.
Freeman SD; Institute of Immunology and Immunotherapy, Department of Clinical Immunology, University of Birmingham, Birmingham, United Kingdom.
Burnett AK; Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom; and.
Russell NH; Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom.
Hills RK; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
Linch DC; Department of Haematology, University College London Cancer Institute, London, United Kingdom.
Pokaż więcej
Źródło :
Blood [Blood] 2018 Jan 25; Vol. 131 (4), pp. 468-471. Date of Electronic Publication: 2017 Dec 11.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Polymorphism, Single Nucleotide*
Aminoglycosides/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Sialic Acid Binding Ig-like Lectin 3/*genetics
Adult ; Clinical Trials as Topic ; Gemtuzumab ; Humans ; Leukemia, Myeloid, Acute/genetics ; Treatment Outcome ; Young Adult
Raport
Tytuł :
Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.
Autorzy :
El-Sharkawi D; Department of Haematology, UCL Cancer Institute, London.
Sproul D; MRC Human Genetics Unit and Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh.
Allen CG; Department of Haematology, UCL Cancer Institute, London.
Feber A; Medical Genomics, UCL Cancer Institute, London.
Wright M; Centre for Trials Research, Cardiff University, UK.
Hills RK; Centre for Trials Research, Cardiff University, UK.
Linch DC; Department of Haematology, UCL Cancer Institute, London.
Gale RE; Department of Haematology, UCL Cancer Institute, London .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2018 Jan; Vol. 103 (1), pp. 91-100. Date of Electronic Publication: 2017 Oct 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Methylation*
Mutation*
CCAAT-Enhancer-Binding Proteins/*genetics
Leukemia, Myeloid, Acute/*genetics
Adult ; Biomarkers, Tumor ; Follow-Up Studies ; Gene Expression Profiling ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/mortality ; Middle Aged ; Prognosis ; Survival Analysis ; Transcriptome
Czasopismo naukowe
Tytuł :
Telomere length is an independent prognostic marker in MDS but not in de novo AML.
Autorzy :
Williams J; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Heppel NH; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Britt-Compton B; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Grimstead JW; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Jones RE; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Tauro S; Department of Haematology, Ninewells Hospital, Dundee, UK.
Bowen DT; Department of Haematology, St James's Institute of Oncology, Leeds, UK.
Knapper S; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Groves M; Department of Haematology, Ninewells Hospital, Dundee, UK.
Hills RK; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Pepper C; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Baird DM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Fegan C; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2017 Jul; Vol. 178 (2), pp. 240-249. Date of Electronic Publication: 2017 May 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute/*pathology
Myelodysplastic Syndromes/*pathology
Telomere/*pathology
Adult ; Aged ; Biomarkers, Tumor/metabolism ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/enzymology ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Myelodysplastic Syndromes/enzymology ; Myelodysplastic Syndromes/mortality ; Prognosis ; Prospective Studies ; Risk Factors ; Telomerase/metabolism ; Young Adult
Czasopismo naukowe
Tytuł :
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Autorzy :
Knapper S; Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom.
Russell N; Department of Haematology, Nottingham University Hospital, Nottingham, United Kingdom.
Gilkes A; Experimental Cancer Medicine Centre, Cardiff University School of Medicine, Cardiff, United Kingdom.
Hills RK; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom.
Gale RE; Department of Haematology, University College London Cancer Institute, London, United Kingdom; Department of Haematology, Bart's Health NHS Trust, London, United Kingdom.
Cavenagh JD; Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom.
Jones G; Department of Haematology, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom.
Kjeldsen L; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
Thomas I; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom.
Konig H; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and.
Levis MJ; Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD.
Burnett AK; Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom.
Pokaż więcej
Źródło :
Blood [Blood] 2017 Mar 02; Vol. 129 (9), pp. 1143-1154. Date of Electronic Publication: 2016 Nov 21.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carbazoles/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Consolidation Chemotherapy ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Induction Chemotherapy ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Mutation ; Proportional Hazards Models ; Protein Kinase Inhibitors/administration & dosage ; Young Adult ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Autorzy :
Ferguson P; Queen Elizabeth Hospital Birmingham NHS Foundation Trust, UK.
Hills RK; Cardiff University School of Medicine, UK.
Grech A; Cardiff University School of Medicine, UK.
Betteridge S; Cardiff University School of Medicine, UK.
Kjeldsen L; Copenhagen University Hospital, Denmark.
Dennis M; The Christie NHS Foundation Trust, Manchester, UK.
Vyas P; University of Oxford and Oxford University Hospitals NHS Trust, UK.
Goldstone AH; University College Hospital, London, UK.
Milligan D; Birmingham Heartlands Hospital, UK.
Clark RE; Royal Liverpool University Hospital, UK.
Russell NH; Nottingham University Hospital, UK.
Craddock C
Pokaż więcej
Corporate Authors :
UK NCRI AML Working Group
Źródło :
Haematologica [Haematologica] 2016 Nov; Vol. 101 (11), pp. 1351-1358. Date of Electronic Publication: 2016 Aug 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Patient Selection*
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Salvage Therapy/*methods
Stem Cell Transplantation/*methods
Adult ; Age Factors ; Aged ; Allografts ; Combined Modality Therapy ; Female ; Humans ; Karyotyping ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Remission Induction ; Retrospective Studies ; Risk Factors ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies